Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI21028350 |
Pages: 260 |
Jul 2022 |
The blood stream infection/sepsis is concern for human due to high morbidity and mortality rates. Globally, it is estimated to affect 30 million people, leading to 6 million deaths every year. For detection and diagnosis of the infection, the in-vitro diagnostic techniques (blood cultures) are widely used. In the microbiology laboratory, technological developments in molecular approaches including in situ hybridization, DNA-microassay-based hybridization method and nucleic acid amplification-based technique have transformed the diagnosis of microbial infections. As the blood stream infection analyzing devices have become faster, more automated, and easier to use, they have become essential part of routine testing and repertoire in most diagnostic laboratories. According to World Health Organization (WHO), there were about 48.9 million sepsis cases and 11 million sepsis-related deaths worldwide in 2017, accounting for nearly 20% of all global deaths. In 2017, children accounted for nearly half of all global sepsis cases, with an estimated 20 million cases and 2.9 million global deaths in children under the age of five.
Several technologically advanced products that provide enhanced solutions for the detection of microorganisms in the blood stream have been introduced in the market in recent years. These advanced products are expected to cannibalize the market for traditional products such as microscopes and polystainers, affecting revenue growth of traditional blood culture testing products. To remain competitive in the market, key players will need to diversify their product portfolio by incorporating new technologies. This will be a difficult task for market participants who have a well-established portfolio of conventional products.
One of the key factors that will create opportunities in market is rise in prevalence of chronic and infectious diseases around the world. Furthermore, increasing geriatric population, which is more susceptible to sepsis and other medical ailments, is fueling the market growth. Laboratories, diagnostic centers, and other healthcare facilities are increasingly using these tests to detect the presence of antibodies in the blood as well as identify and isolate infected individuals. Other factors, such as rising health consciousness among the general population, improvements in healthcare infrastructure, and extensive Research and Development (R&D) activities in the field of medical sciences, are expected to create investment opportunities for the major players in the market.
Blood stream infection is the infectious disease caused due to presence of bacteria, pathogen, or fungi microorganism in systemic circulation which evokes the inflammatory response by altering the physiochemical aspects of body. For identifying the infection, the blood sample is taken from blood stream and evaluated by laboratories, diagnostic centers, and other healthcare facilities.
In 2020, the COVID-19 outbreak caused global public health emergency and brought the world to a halt, affecting every other sector. COVID-19 impact on blood stream infection testing market is positive. A blood culture is considered as the global standard for diagnosis of the infection or pathogen which is expected to increase the demand for blood stream infection testing. The rise in cases of COVID-19 and sepsis in North America and Europe boosted the growth of blood stream testing. The incidence rate of blood stream infection in global COVID-19 patient was found to be 0.863% compared to patients without COVID having 0.437%, which increased the requirement for diagnosis of pathogens or microbes during the pandemic. As the coronavirus has been undergoing mutation, it is likely that the blood stream infection testing will rise in near future. Advancements in blood stream testing methods have greatly impacted the diagnosis of infection or pathogen. These advancements require less time for analysis of blood cultures compared to traditional methods of blood culture analysis. The increased investment in the blood stream testing R&D and production is expected to drive the blood stream testing market expansion.
The increase in the number of sepsis and bacteremia cases globally is expected to drive the blood stream infection testing market. Bacteremia and sepsis are few of the top causes of mortality rate in U.S., causing over 600 fatalities each day. Thus the need for rapid and precise diagnosis has increased to identify the pathogen and recent advancement in blood stream infection testing are expected to boost the market growth. The increasing incidences of blood stream infection in elderly population who are susceptible to infection due to low immunity is anticipated to drive the demand for blood stream infection testing and boost the growth of the market.
To know more about global blood stream infection testing market drivers, get in touch with our analysts here.
The recent advancement in technology of instruments for rapid and accurate testing has increased the cost of the testing. Also, introduction to automated machines such as MALDI-TOF, DOT, and others are novel technologies which can diagnosis blood infection with high accuracy and precision, but has significantly increased the cost of diagnostic instruments for blood stream infections. Thus high purchasing cost and maintenance cost of these instruments is expected restrain the market growth over the forecast period. Furthermore, lack of medical reimbursement for these advanced blood stream testing for diagnosis of infection is expected to hinder the blood stream infection testing market growth.
In 2019, the global population of people over 65 was near 1 billion, and according to WHO, an international public health agency, the population of people above 65 is expected to increase to 1.4 billion by 2030. The increase in global geriatric population which is prone to infection is expected to drive revenue growth of the market. The significance of quick and accurate medical examinations as a result of COVID-19 is expected to drive the market growth. To identify diseases and do proper diagnosis, scientists are developing low-cost and quick methods. Methods such as antibiotic susceptibility testing, high-throughput blood processing, and high sensitivity pathogen detection are anticipated to provide investment opportunities for key players in the market.
To know more about global blood stream infection testing market opportunities, get in touch with our analysts here.
Based on product, the market has been divided into instruments, consumables, and software & services. Among these consumables sub-segment accounted for the highest market share in 2021 and expected to dominate market in near future.
Source: Research Dive Analysis
The consumables sub-segment is anticipated to have dominant market share and generate a revenue of $8,505.3 million by 2030, increasing from $4,119.4 million in 2021. The consumables used in the blood stream testing include syringes, needle, bandage, test tubes, and reagents, and others such as tourniquets, alcohol-swabs, gauze pads, and bandages. The increase in blood stream testing by recommendation by doctor to analyze the pathogen, so particular antibiotics can be provided to eliminate the pathogen rather than depending on the broad spectrum antibiotics.
The instruments sub-segment is expected to show fastest growth in the market and generate a revenue of $1,535.7 million by 2030, growing from $732.2 million in 2021. The improvement in healthcare services in several hospitals, clinics, diagnostic centers are upgrading their instruments with more modern and technological advanced instruments. The many companies such as Axiomtek is focusing on improving existing technology in computing technology of instrument for better performance of instrumentation.
Based on technique, the market has been divided into conventional and automated. Among these, the conventional sub-segment is expected to be dominant in market share and the automated sub-segment is expected to show fastest growth in the market.
Source: Research Dive Analysis
The automated sub-segment is expected to show fastest growth in blood stream infection testing market and generate a revenue of $3,280.1 million by 2030, increasing from $1,504 million in 2021. As automated medical instruments are much more efficient than traditional ones and produce more accurate and reliable results, and they are in high demand due to increase in development of the healthcare sector. These factors are expected to drive the growth of this sub-segment.
Based on technology, the market has been divided into culture-based, molecular, and proteomic. Among these, the culture-based sub-segment is expected to be dominant in the market share and the molecular sub-segment is expected to show fastest growth in the market.
Source: Research Dive Analysis
The culture-based sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $6,092.1 million by 2030, increasing from $3,123.1 million in 2021. The most widely used method is culture-based in blood testing and has remained best for blood stream infection detection as it can detect various bacteria present in blood as well as fungi.
Based on application, the market has been divided into bacterial, fungal, and mycobacterial. Among these, the bacterial sub-segment is anticipated to be dominant in market share and the fungal sub-segment is expected to show fastest growth in the market.
Source: Research Dive Analysis
The bacterial sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,776.6 million by 2030, increasing from $2,709.3 million in 2021. In 2019, around 1.27 million deaths occurred due to antimicrobial resistance bacterial infection, thus it is important to diagnose the bacterial infection precisely to treat the antimicrobial resistance bacteria. This factor is expected to drive the growth of this sub-segment.
Based on end-user, the market has been divided into hospitals, independent diagnostics centers, others. Among these, the independent diagnostics center sub-segment is expected to show fastest growth in market and the hospital sub-segment is expected to be dominant in market share.
Source: Research Dive Analysis
The hospitals sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,247.1 million by 2030, increasing from $2,665.6 million in 2021. The improvement in healthcare facilities is major driving factor for this sub-segment. Due to pandemic the healthcare system was overwhelmed and to improve facilities, several hospitals are expected to improve their laboratories for blood testing which will be major driving factor for blood stream infection testing market.
The blood stream infection testing market outlook was investigated across North America, Europe, Asia-Pacific, and LAMEA.
Global Blood Stream Infection Testing Market Size & Forecast, by Region, 2022-2030 (USD Million)
Source: Research Dive Analysis
The North America blood stream infection testing market trend generated a revenue of $2,084.8 million in 2021 and is predicted to grow at significant CAGR of 7.8%. Increasing geriatric population in the U.S. and Canada will give rise to blood stream infection testing as the geriatric population are more prone to communicable disease due to their poor immunity. Presence of a large number of healthcare facilities in the U.S. is worth more than $800 billion and easy access to the healthcare facilities is expected to generate maximum revenue drive the growth of the blood stream infection testing market opportunity. Furthermore, the bacteremia is found out to be one of major cause of mortality in the U.S., thus need for of companies investing more in research and development of blood stream infection testing devices for better and faster diagnostic are expected to create market opportunities during the forecast period.
Source: Research Dive Analysis
The major key players in the global blood stream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton Dickinson, bioMérieux SA, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker Corp.
| Aspect | Particulars |
| Historical Market Estimations | 2020-2021 |
| Base Year for Market Estimation | 2021 |
| Forecast timeline for Market Projection | 2022-2030 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Product |
|
| Segmentation by Technique |
|
| Segmentation by Technology |
|
| Segmentation by Application |
|
| Segmentation by End-user |
|
| Key Companies Profiled |
|
1.Research Methodology
1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach
2.Report Scope
2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on Global blood stream infection testing market
3.Executive Summary
4.Market Overview
4.1.Introduction
4.2.Growth impact forces
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities
4.3.Market value chain analysis
4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors
4.4.Innovation & sustainability matrices
4.4.1.Technology matrix
4.4.2.Regulatory matrix
4.5.Porter’s five forces analysis
4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity
4.6.PESTLE analysis
4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental
4.7.Impact of COVID-19 on blood stream infection testing market
4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario
5.Blood Stream Infection Testing Market Analysis, by Product
5.1.Overview
5.2.Consumables
5.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.2.2.Market size analysis, by region, 2021-2030
5.2.3.Market share analysis, by country, 2021-2030
5.3.Instruments
5.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.3.2.Market size analysis, by region, 2021-2030
5.3.3.Market share analysis, by country, 2021-2030
5.4.Software & Services
5.4.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.4.2.Market size analysis, by region, 2021-2030
5.4.3.Market share analysis, by country, 2021-2030
5.5.Research Dive Exclusive Insights
5.5.1.Market attractiveness, 2021-2030
5.5.2.Competition heatmap, 2021-2030
6.Blood Stream Infection Testing Market Analysis, by Technique
6.1.Conventional
6.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
6.1.2.Market size analysis, by region, 2021-2030
6.1.3.Market share analysis, by country, 2021-2030
6.2.Automated
6.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
6.2.2.Market size analysis, by region, 2021-2030
6.2.3.Market share analysis, by country, 2021-2030
6.3.Research Dive Exclusive Insights
6.3.1.Market attractiveness, 2021-2030
6.3.2.Competition heatmap, 2021-2030
7.Blood Stream Infection Testing Market Analysis, by Technology
7.1.Culture-based
7.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.1.2.Market size analysis, by region, 2021-2030
7.1.3.Market share analysis, by country, 2021-2030
7.2.Molecular
7.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.2.2.Market size analysis, by region, 2021-2030
7.2.3.Market share analysis, by country, 2021-2030
7.3.Proteomic
7.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.3.2.Market size analysis, by region, 2021-2030
7.3.3.Market share analysis, by country, 2021-2030
7.4.Research Dive Exclusive Insights
7.4.1.Market attractiveness, 2021-2030
7.4.2.Competition heatmap, 2021-2030
8.Blood Stream Infection Testing Market Analysis, by Application
8.1.Bacterial
8.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.1.2.Market size analysis, by region, 2021-2030
8.1.3.Market share analysis, by country, 2021-2030
8.2.Fungal
8.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.2.2.Market size analysis, by region, 2021-2030
8.2.3.Market share analysis, by country, 2021-2030
8.3.Mycobacterial
8.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.3.2.Market size analysis, by region, 2021-2030
8.3.3.Market share analysis, by country, 2021-2030
8.4.Research Dive Exclusive Insights
8.4.1.Market attractiveness, 2021-2030
8.4.2.Competition heatmap, 2021-2030
9.Blood Stream Infection Testing Market Analysis, by End-user
9.1.Hospitals
9.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.1.2.Market size analysis, by region, 2021-2030
9.1.3.Market share analysis, by country, 2021-2030
9.2.Independent Diagnostics Centers
9.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.2.2.Market size analysis, by region, 2021-2030
9.2.3.Market share analysis, by country, 2021-2030
9.3.Others
9.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.3.2.Market size analysis, by region, 2021-2030
9.3.3.Market share analysis, by country, 2021-2030
9.4.Research Dive Exclusive Insights
9.4.1.Market attractiveness, 2021-2030
9.4.2.Competition heatmap, 2021-2030
10.Blood Stream Infection Testing Market, by Region
10.1.North America
10.1.1.U.S.
10.1.1.1.Market size analysis, by Product, 2021-2030
10.1.1.2.Market size analysis, by Technique, 2021-2030
10.1.1.3.Market size analysis, by Technology, 2021-2030
10.1.1.4.Market size analysis, by Application, 2021-2030
10.1.1.5.Market size analysis, by End-user, 2021-2030
10.1.2.Canada
10.1.2.1.Market size analysis, by Product, 2021-2030
10.1.2.2.Market size analysis, by Technique, 2021-2030
10.1.2.3.Market size analysis, by Technology, 2021-2030
10.1.2.4.Market size analysis, by Application, 2021-2030
10.1.2.5.Market size analysis, by End-user, 2021-2030
10.1.3.Mexico
10.1.3.1.Market size analysis, by Product, 2021-2030
10.1.3.2.Market size analysis, by Technique, 2021-2030
10.1.3.3.Market size analysis, by Technology, 2021-2030
10.1.3.4.Market size analysis, by Application, 2021-2030
10.1.3.5.Market size analysis, by End-user, 2021-2030
10.1.4.Research Dive Exclusive Insights
10.1.4.1.Market attractiveness, 2021-2030
10.1.4.2.Competition heatmap, 2021-2030
10.2.Europe
10.2.1.Germany
10.2.1.1.Market size analysis, by Product, 2021-2030
10.2.1.2.Market size analysis, by Technique, 2021-2030
10.2.1.3.Market size analysis, by Technology, 2021-2030
10.2.1.4.Market size analysis, by Application, 2021-2030
10.2.1.5.Market size analysis, by End-user, 2021-2030
10.2.2.U.K.
10.2.2.1.Market size analysis, by Product, 2021-2030
10.2.2.2.Market size analysis, by Technique, 2021-2030
10.2.2.3.Market size analysis, by Technology, 2021-2030
10.2.2.4.Market size analysis, by Application, 2021-2030
10.2.2.5.Market size analysis, by End-user, 2021-2030
10.2.3.France
10.2.3.1.Market size analysis, by Product, 2021-2030
10.2.3.2.Market size analysis, by Technique, 2021-2030
10.2.3.3.Market size analysis, by Technology, 2021-2030
10.2.3.4.Market size analysis, by Application, 2021-2030
10.2.3.5.Market size analysis, by End-user, 2021-2030
10.2.4.Spain
10.2.4.1.Market size analysis, by Product, 2021-2030
10.2.4.2.Market size analysis, by Technique, 2021-2030
10.2.4.3.Market size analysis, by Technology, 2021-2030
10.2.4.4.Market size analysis, by Application, 2021-2030
10.2.4.5.Market size analysis, by End-user, 2021-2030
10.2.5.Italy
10.2.5.1.Market size analysis, by Product, 2021-2030
10.2.5.2.Market size analysis, by Technique, 2021-2030
10.2.5.3.Market size analysis, by Technology, 2021-2030
10.2.5.4.Market size analysis, by Application, 2021-2030
10.2.5.5.Market size analysis, by End-user, 2021-2030
10.2.6.Rest of Europe
10.2.6.1.Market size analysis, by Product, 2021-2030
10.2.6.2.Market size analysis, by Technique, 2021-2030
10.2.6.3.Market size analysis, by Technology, 2021-2030
10.2.6.4.Market size analysis, by Application, 2021-2030
10.2.6.5.Market size analysis, by End-user, 2021-2030
10.2.7.Research Dive Exclusive Insights
10.2.7.1.Market attractiveness, 2021-2030
10.2.7.2.Competition heatmap, 2021-2030
10.3.Asia-Pacific
10.3.1.China
10.3.1.1.Market size analysis, by Product, 2021-2030
10.3.1.2.Market size analysis, by Technique, 2021-2030
10.3.1.3.Market size analysis, by Technology, 2021-2030
10.3.1.4.Market size analysis, by Application, 2021-2030
10.3.1.5.Market size analysis, by End-user, 2021-2030
10.3.2.Japan
10.3.2.1.Market size analysis, by Product, 2021-2030
10.3.2.2.Market size analysis, by Technique, 2021-2030
10.3.2.3.Market size analysis, by Technology, 2021-2030
10.3.2.4.Market size analysis, by Application, 2021-2030
10.3.2.5.Market size analysis, by End-user, 2021-2030
10.3.3.India
10.3.3.1.Market size analysis, by Product, 2021-2030
10.3.3.2.Market size analysis, by Technique, 2021-2030
10.3.3.3.Market size analysis, by Technology, 2021-2030
10.3.3.4.Market size analysis, by Application, 2021-2030
10.3.3.5.Market size analysis, by End-user, 2021-2030
10.3.4.Australia
10.3.4.1.Market size analysis, by Product, 2021-2030
10.3.4.2.Market size analysis, by Technique, 2021-2030
10.3.4.3.Market size analysis, by Technology, 2021-2030
10.3.4.4.Market size analysis, by Application, 2021-2030
10.3.4.5.Market size analysis, by End-user, 2021-2030
10.3.5.South Korea
10.3.5.1.Market size analysis, by Product, 2021-2030
10.3.5.2.Market size analysis, by Technique, 2021-2030
10.3.5.3.Market size analysis, by Technology, 2021-2030
10.3.5.4.Market size analysis, by Application, 2021-2030
10.3.5.5.Market size analysis, by End-user, 2021-2030
10.3.6.Rest of Asia-Pacific
10.3.6.1.Market size analysis, by Product, 2021-2030
10.3.6.2.Market size analysis, by Technique, 2021-2030
10.3.6.3.Market size analysis, by Technology, 2021-2030
10.3.6.4.Market size analysis, by Application, 2021-2030
10.3.6.5.Market size analysis, by End-user, 2021-2030
10.3.7.Research Dive Exclusive Insights
10.3.7.1.Market attractiveness, 2021-2030
10.3.7.2.Competition heatmap, 2021-2030
10.4.LAMEA
10.4.1.Brazil
10.4.1.1.Market size analysis, by Product, 2021-2030
10.4.1.2.Market size analysis, by Technique, 2021-2030
10.4.1.3.Market size analysis, by Technology, 2021-2030
10.4.1.4.Market size analysis, by Application, 2021-2030
10.4.1.5.Market size analysis, by End-user, 2021-2030
10.4.2.Saudi Arabia
10.4.2.1.Market size analysis, by Product, 2021-2030
10.4.2.2.Market size analysis, by Technique, 2021-2030
10.4.2.3.Market size analysis, by Technology, 2021-2030
10.4.2.4.Market size analysis, by Application, 2021-2030
10.4.2.5.Market size analysis, by End-user, 2021-2030
10.4.3.UAE
10.4.3.1.Market size analysis, by Product, 2021-2030
10.4.3.2.Market size analysis, by Technique, 2021-2030
10.4.3.3.Market size analysis, by Technology, 2021-2030
10.4.3.4.Market size analysis, by Application, 2021-2030
10.4.3.5.Market size analysis, by End-user, 2021-2030
10.4.4.South Africa
10.4.4.1.Market size analysis, by Product, 2021-2030
10.4.4.2.Market size analysis, by Technique, 2021-2030
10.4.4.3.Market size analysis, by Technology, 2021-2030
10.4.4.4.Market size analysis, by Application, 2021-2030
10.4.4.5.Market size analysis, by End-user, 2021-2030
10.4.5.Rest of LAMEA
10.4.5.1.Market size analysis, by Product, 2021-2030
10.4.5.2.Market size analysis, by Technique, 2021-2030
10.4.5.3.Market size analysis, by Technology, 2021-2030
10.4.5.4.Market size analysis, by Application, 2021-2030
10.4.5.5.Market size analysis, by End-user, 2021-2030
10.4.6.Research Dive Exclusive Insights
10.4.6.1.Market attractiveness, 2021-2030
10.4.6.2.Competition heatmap, 2021-2030
11.Competitive Landscape
11.1.Top winning strategies, 2021
11.1.1.By strategy
11.1.2.By year
11.2.Strategic overview
11.3.Market share analysis, 2021
12.Company Profiles
12.1. Thermo Fisher Scientific
12.1.1.Overview
12.1.2.Business segments
12.1.3.Product portfolio
12.1.4.Financial performance
12.1.5.Recent developments
12.1.6.SWOT analysis
12.2.F. Hoffmann-La Roche Ltd
12.2.1.Overview
12.2.2.Business segments
12.2.3.Product portfolio
12.2.4.Financial performance
12.2.5.Recent developments
12.2.6.SWOT analysis
12.3.Abbott
12.3.1.Overview
12.3.2.Business segments
12.3.3.Product portfolio
12.3.4.Financial performance
12.3.5.Recent developments
12.3.6.SWOT analysis
12.4. BD
12.4.1.Overview
12.4.2.Business segments
12.4.3.Product portfolio
12.4.4.Financial performance
12.4.5.Recent developments
12.4.6.SWOT analysis
12.5.BIOMÉRIEUX
12.5.1.Overview
12.5.2.Business segments
12.5.3.Product portfolio
12.5.4.Financial performance
12.5.5.Recent developments
12.5.6.SWOT analysis
12.6.Cepheid.
12.6.1.Overview
12.6.2.Business segments
12.6.3.Product portfolio
12.6.4.Financial performance
12.6.5.Recent developments
12.6.6.SWOT analysis
12.7.Luminex Corporation
12.7.1.Overview
12.7.2.Business segments
12.7.3.Product portfolio
12.7.4.Financial performance
12.7.5.Recent developments
12.7.6.SWOT analysis
12.8.Accelerate Diagnostics
12.8.1.Overview
12.8.2.Business segments
12.8.3.Product portfolio
12.8.4.Financial performance
12.8.5.Recent developments
12.8.6.SWOT analysis
12.9.AdvanDX
12.9.1.Overview
12.9.2.Business segments
12.9.3.Product portfolio
12.9.4.Financial performance
12.9.5.Recent developments
12.9.6.SWOT analysis
12.10.Bruker
12.10.1.Overview
12.10.2.Business segments
12.10.3.Product portfolio
12.10.4.Financial performance
12.10.5.Recent developments
12.10.6.SWOT analysis
13.Appendix
13.1.Parent & peer market analysis
13.2.Premium insights from industry experts
13.3.Related reports
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization
